Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + sipuleucel-T
- Development stage
- Unknown
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ipilimumab + sipuleucel-T is a combination immunotherapy regimen investigated for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). This therapeutic approach combines ipilimumab, a fully human monoclonal antibody that inhibits the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint, with sipuleucel-T, an autologous cellular immunotherapy. Sipuleucel-T is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, by using patient-derived peripheral blood mononuclear cells activated ex vivo with a recombinant fusion protein (PA2024). The rationale for the combination is that CTLA-4 blockade by ipilimumab can augment the T-cell response primed by sipuleucel-T. A Phase 2 randomized trial (NCT01804465) conducted by the University of California, San Francisco (UCSF) and MD Anderson Cancer Center evaluated the efficacy and timing of this combination, comparing immediate versus delayed ipilimumab administration following sipuleucel-T treatment.
- Brand names
- YervoyProvenge
- Other names
- ipilimumab and sipuleucel-T combination
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on ipilimumab + sipuleucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + sipuleucel-T.